Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novozymes Biopharma has introduced Albufuse Flex technology, an enhanced next-generation albumin technology, to help the users in adapting and controlling the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.
Subscribe to our email newsletter
Developed in collaboration with the University of Oslo, Norway, Albufuse Flex technology will facilitate manipulation based on this FcRn-albumin interaction, enabling a tunable half-life that offers control and flexibility and that, potentially, may improve overall treatment efficacy and patient compliance.
The enhanced technology offers delivery vehicle for small molecules, providing a broad scope of usability.
Norwegian Centre of Excellence for Immune Regulation group leader Inger Sandlie said the efficacy of peptides, small proteins, and engineered antibody fragments is hampered by short serum half-life.
"Albufuse Flex technology solves this problem and will result in enhanced treatment efficacy, more favorable dosing regimes, and improved patient compliance," Sandlie said.